How are SEPN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SEPN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 121.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$615.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a SEPN strangle?

The breakeven for the SEPN strangle priced on this page is roughly $26.85 and $43.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SEPN market-implied 1-standard-deviation expected move is approximately 34.80%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current SEPN implied volatility affect this strangle?

SEPN ATM IV is at 121.40% with IV rank near 35.42%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

SEPN Strangle Strategy

SEPN (Septerna Inc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

SEPN (Septerna Inc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.68B, a beta of 2.38 versus the broader market, a 52-week range of 10.3-37.99, average daily share volume of 348K, a public-listing history dating back to 2024, approximately 130 full-time employees. These structural characteristics shape how SEPN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.38 indicates SEPN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on SEPN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current SEPN snapshot

As of June 29, 2026, spot at $35.19, ATM IV 121.40%, IV rank 35.42%, expected move 34.80%. The strangle on SEPN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on SEPN specifically: SEPN IV at 121.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 34.80% (roughly $12.25 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SEPN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SEPN should anchor to the underlying notional of $35.19 per share and to the trader's directional view on SEPN stock.

SEPN strangle setup

The SEPN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SEPN near $35.19, the first option leg uses a $37.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SEPN chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SEPN shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$37.00	$2.95
Buy 1	Put	$33.00	$3.20

SEPN strangle risk and reward

Net Premium / Debit: -$615.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$615.00
Breakeven(s): $26.85, $43.15
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

SEPN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on SEPN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$2,684.00
$7.79	-77.9%	+$1,906.04
$15.57	-55.8%	+$1,128.08
$23.35	-33.6%	+$350.12
$31.13	-11.5%	-$427.84
$38.91	+10.6%	-$424.20
$46.69	+32.7%	+$353.76
$54.47	+54.8%	+$1,131.72
$62.25	+76.9%	+$1,909.68
$70.03	+99.0%	+$2,687.64

When traders use strangle on SEPN

Strangles on SEPN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SEPN chain.

SEPN thesis for this strangle

The market-implied 1-standard-deviation range for SEPN extends from approximately $22.94 on the downside to $47.44 on the upside. A SEPN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SEPN IV rank near 35.42% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SEPN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SEPN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SEPN-specific events.

SEPN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SEPN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SEPN alongside the broader basket even when SEPN-specific fundamentals are unchanged. Always rebuild the position from current SEPN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on SEPN?: A strangle on SEPN is the strangle strategy applied to SEPN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SEPN stock trading near $35.19, the strikes shown on this page are snapped to the nearest listed SEPN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SEPN strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SEPN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 121.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$615.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SEPN strangle?: The breakeven for the SEPN strangle priced on this page is roughly $26.85 and $43.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SEPN market-implied 1-standard-deviation expected move is approximately 34.80%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on SEPN?: Strangles on SEPN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SEPN chain.
How does current SEPN implied volatility affect this strangle?: SEPN ATM IV is at 121.40% with IV rank near 35.42%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.